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Objective: To investigate the efﬁcacy of recombinant human soluble thrombomodulin (rTM) in pre-
venting the development of walled-off necrosis (WON) in severe acute pancreatitis (SAP) patients.
Methods: We retrospectively analyzed 54 SAP patients divided into two groups: SAP patients treated by
rTM (rTM group, 24 patients) and not treated by rTM (control group, 30 patients). rTM was administered
to patients with disseminated intravascular coagulation (DIC). Initially, on the admission day, we
recorded patient severity and pancreatic necrosis/ischemia positive or negative. Then we investigated
development of WON using 4 weeks later CT/MRI. Finally we compared the proportions of patients
developing WON in the rTM group and the control group.
Results: On the admission day, the condition of patients treated by rTM was signiﬁcantly worse than
patients in the control group; rTM group vs. control: 71.8 ± 13.9 vs. 59.8 ± 15.3 years for age, 10.7 ± 3.5 vs.
8.0 ± 4.4 for Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and 3.3 ± 1.8 vs.
2.2 ± 1.8 for sequential organ failure assessment (SOFA) score (p < 0.05). We found no signiﬁcant dif-
ferences on the admission day in rate of pancreatic necrosis/ischemia between patients treated by rTM
and controls (58.3% vs. 63.3%, p ¼ 0.71). Nevertheless, the proportion of patients developing WON was
signiﬁcantly lower among those administered rTM than in those not administered rTM {29.2% (7/24
patients) vs. 56.7% (17/30 patients), p < 0.05}.
Conclusion: Treatment of SAP patients treated by rTM may prevent progression from pancreatic necrosis/
ischemia to WON.
Copyright © 2015, IAP and EPC. Published by Elsevier India, a division of Reed Elsevier India Pvt. Ltd. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Severe acute pancreatitis (SAP) is a potentially high mortality
disease. Organ failure (OF) is among the major reasons for this high
mortality. Pancreatitis-related OFs are either local or systemic. In
general, local OF can be divided into three stages: pancreatic
ischemia, pancreatic necrosis, and walled-off necrosis (WON) [1].
Pancreatic necrosis is caused by pancreatic ischemia, which leads to
WON. Systemic OF, including shock states, respiratory failure, renalx: þ81 06 6372 8739.
).
by Elsevier India, a division of Reedfailure, and heart failure, is the common origin of patient instability
[2e5]. Both local and systemic OFs can be caused by abnormal
coagulability, which causes from the endovascular damage caused
by pancreatitis.
Some articles report that endovascular damage in acute
pancreatitis patients is related to the development of disseminated
intravascular coagulation (DIC). Other studies indicate that a high
proportion of acute pancreatitis patients with early DIC may
develop OFs. Importantly, acute pancreatitis with DIC is associated
with high mortality [5e8]. In the light of these reports, controlling
DIC in the early stage of acute pancreatitis may help prevent the
development of local and systemic OFs, thereby reducing mortality.
However, to the best of our knowledge, no effective treatmentElsevier India Pvt. Ltd. This is an open access article under the CC BY-NC-ND license
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acute pancreatitis. For example, in recent pancreatitis and DIC
practical guidelines deprecate the usefulness of heparin or similar
anti-coagulant drugs [9e11]. Evidence for the efﬁcacy of activated
recombinant protein C or anti-thrombin III also remains insufﬁcient
[12e16].
Recently, recombinant human soluble thrombomodulin (rTM)
has been used to treat patients with DIC in Japan, and a phase III
clinical trial evaluating the efﬁcacy of rTM in severe sepsis patients
with DIC is now ongoing in the USA, South America, Asia, Australia,
European Union, and other countries [17e23]. Several studies
report that rTM has anti-coagulation effects, resulting in im-
provements in septic DIC [20e28]. However, the clinical effective-
ness of rTM for acute pancreatitis patients with DIC has not been
assessed.
This study investigates whether rTM prevents local and/or
systemic OFs in acute pancreatitis patients.
Patients and methods
Patients
This study was approved by the institutional review board of
Osaka Saiseikai Nakatsu Hospital. From January 2006 to December
2013, we reviewed all pancreatitis patients data in our hospital,
retrospectively. Then, >18 years old patients with SAP diagnosed by
Japanese criteria were enrolled in this study. Also, patients with
cancer related pancreatitis and/or immunosuppressed patients
were excluded. Thereby, 54 patients with SAP were enrolled in this
study. All patient data was gathered from an electronic database.
Age, gender, and etiology were recorded from chart reviews. A
diagnosis of acute pancreatitis was made based on 2 of 3 of the
following symptoms: abdominal pain, abnormal elevation of
amylase and/or lipase, and pancreatic inﬂammation indicated by
computed tomography (CT) imaging [6,29]. SAP was diagnosed
using Japanese severity scoring system. The study enrolled patients
with SAP whose treatment began within 48 h of onset.
Assessment of severity
To evaluate the severity of acute pancreatitis, C-reactive protein
(CRP) [2], number of patients with Blood Urea Nitrogen (BUN)
20 mg/dl [30], Acute Physiology and Chronic Health Evaluation II
(APACHE II) score [31,32], Systemic Inﬂammatory Response Syn-
drome (SIRS) score [33], Sequential Organ Failure Assessment
(SOFA) score [34], and Japanese severity score [35] were calculated
before treatment (admission day ¼ day 0) and after the start of
treatment (day 3 and 7), based on retrospective reviews of medical
charts. A diagnosis of pancreatic necrosis (or ischemia) based on
conventional contrast-enhanced CT (CECT) was recorded. Also,
patients with acute necrotizing collection (ANC) 6 cm (maximum
transverse diameter) (n ¼ 20) was measured based on CT or mag-
netic resonance imaging (MRI) image.
We deﬁned organ failure as the followings: renal failure: serum
creatinine >1.9 mg/dL; respiratory failure: PaO2/FiO2 ratio
<300 mmHg; central nervous system failure: Glasgow coma score
<13; coagulopathy: platelet count 8.0  1010/L; and cardiovas-
cular failure: systolic blood pressure 90 mmHg despite ﬂuid
replacement [36]. We deﬁned persistent organ failure (POF) as or-
gan failure persisting for at least 48 h.
Clinical outcomes
Length of hospital stay, need for Intensive Care Unit (ICU) care,
length of ICU stay, development of WON and/or POF, and mortalitywere recorded. WON was diagnosed according to revised Atlanta
criteria [37] and previous study [38], using CT or MRI obtained at 4
weeks or later after admission. Single board certiﬁcated radiologist,
who had 20 years over experience as abdominal image, reviewed
blindly all of images.
Treatment strategy for early stage acute pancreatitis
Enrolled patients were treated based on the strategy recom-
mended in the Japanese guidelines for early stage acute pancreatitis
[39e42]: in brief, fasting, aggressive ﬂuid therapy, and adminis-
tration of a protease inhibitor (nafamostat mesilate: 0.06e0.20 mg/
kg/hours infused continuously; gabexate mesilate: 20e39 mg/kg/
day). Continuous regional arterial infusion of the protease inhibitor
(nafamostat mesilate) and prophylactic antibiotics (CRAI) [43e45]
was undertaken for patients with ischemic or necrotizing pancre-
atitis [46,47]. Intravenous antibiotics were admitted for patients
suspected to have sepsis (high fever with shock-like states).
Recombinant human soluble thrombomodulin
All patients with DIC were treated using recombinant human
soluble thrombomodulin (rTM) (Recomodulin® Injection, Asahi
Kasei Pharma Corporation, Tokyo, Japan) (380 U/kg/day or 130 U/
kg/day for patients on hemodialysis) [18]. DIC was diagnosed based
on a JAAM criteria score of 4 points or higher [18,48]. JAAM criteria
assign 1 point for cases involving SIRS, mild thrombopenia (platelet
count 8.0 and <12.0  1010/L, or >30% decrease within 24 h from
admission), and prolongation of prothrombin time-international
normalized ratio (1.2) and mild elevation of ﬁbrin/ﬁbrinogen
degradation products (FDP) values (10 and <25 mg/mL). JAAM
criteria also assign 3 points for severe thrombopenia (<8.0  1010/L
or >50% decrease within 24 h), severe elevation of FDP values
(25 mg/mL). The rTM treatment was maintained until DIC scores
improved to a JAAM score of 3.
Changes involving severity, coagulation abnormality and
inﬂammatory response
We investigated patient severity (CRP, SOFA score, APACHE II
score, JPN score) on day 0, day 3, and day 7. At the same timing of
the severity evaluations, we also measured platelet count, FDP,
plasma thrombineantithrombin III complex (TAT), D-dimer,
Interleukin-6 (IL-6), and high morbidity group box 1 (HMGB-1).
Clinical outcomes patients with and without development of WON
We ﬁnally investigated length of hospital stay, need for ICU care,
length of ICU stay, number and cost of follow-up CT/MRI within 1
year from onset, POF, and mortality, according to patients with and
without development of WON.
Statistical analysis
Of the 54 patients, 24 (44.4%) developed DIC and were treated
by rTM. The patients were divided into two groups, based on
whether rTM was administered or not administered: rTM(þ) (rTM
group, n¼ 24) and rTM() (control group, n¼ 30). Then, outcomes,
and involving severity coagulation abnormality and inﬂammatory
response were compared between rTM group and control group.
Descriptive statistics are presented as mean ± standard devia-
tion (SD) or a number (percent). Between the two groups, values
were compared using the chi-square test or ManneWhitney U test
with Bonferroni corrections. A p-value of <0.05 was deemed to
Table 1
Background of enrolled patients.
Total
n ¼ 54
rTM group
n ¼ 24
Control group
n ¼ 30
Age (years) 65.1 ± 15.8 71.8 ± 13.9* 59.8 ± 15.3
Male/Female 35/19 16/8 19/11
Etiology
Alcohol 20 9 11
Gallstone 9 1 8
Other 25 14 11
rTM: recombinant human soluble thrombomodulin.
*p < 0.05, comparing rTM group to control.
Table 3
Outcomes compared for rTM and control groups.
Total
n ¼ 54
rTM group
n ¼ 24
Control group
n ¼ 30
Length of hospital stay (days) 35.6 ± 31.1 33.8 ± 21.7 37.0 ± 37.2
Need for ICU care 36 (66.6%) 18 (75%) 18 (60.0%)
Length of ICU stay (days) 6.6 ± 6.0 7.1 ± 6.9 6.0 ± 4.5
Walled-off necrosis 24 (44.4%) 7 (29.2%)* 17 (56.7%)
POF 5 (9.3%) 3 (12.5%) 2 (6.7%)
Mortality rate 4 (7.4%) 2 (8.3%) 2 (6.7%)
ICU: Intensive Care Unit; POF: Persistent Organ Failure.
*p < 0.05, comparing rTM group to control.
T. Eguchi et al. / Pancreatology 15 (2015) 485e490 487indicate statistical signiﬁcance. All statistical analyses were per-
formed using SPSS Statistics version 20 (IBM Corp, NY, US).
Results
Background of enrolled patients
Table 1 provides a summary of the background information for
the enrolled patients. Average age and ratio of male/female for all
enrolled patients were 65.1 ± 15.8 years and 35/19, respectively.
Etiologies of acute pancreatitis patients were as follows: alcohol in
20 patients, gallstones in 9, and other in 25. Of the background
factors for the control group and the rTM group, only average age
differed signiﬁcantly (71.8 ± 13.9 vs. 59.8 ± 15.3 years, p < 0.05).
Severity of enrolled patients on admission day
The condition of patients treated by rTMwere signiﬁcantlymore
severe than that of those in the control group {patients with BUN
20 mg/dl: 58.3% (14/24 patients) vs. 23.3% (7/30 patients),
APACHE II score: 10.7 ± 3.5 vs. 8.0 ± 4.4; SOFA score: 3.3 ± 1.8 vs.
2.2 ± 1.8; ratio of SAP on JPN criteria: 62.5 vs. 26.7 [%], p < 0.05}
(Table 2). We found no signiﬁcant differences in CRP value, ratio of
SIRS, ratio of pancreatic necrosis/ischemia, patients with ANC 
6 cm, or organ failure on admission between the rTM and control
groups.
Comparison of outcomes between the rTM and control groups
The rate of development of WON in patients treated by rTMwas
signiﬁcantly lower than those in the control group {29.2% (7/24
patients) vs. 56.7% (17/30 patients), p < 0.05}. On the other hand,Table 2
Severity of enrolled patients at the time of admission.
Total
n ¼ 54
rTM group
n ¼ 24
Control group
n ¼ 30
CRP (mg/dL) 9.9 ± 8.3 12.0 ± 8.7 8.3 ± 7.8
BUN 20 mg/dl 21 (38.8%) 14 (58.3%)* 7 (23.3%)
APACHE II score 9.2 ± 4.2 10.7 ± 3.5 * 8.0 ± 4.4
SIRS 2.2 ± 1.1 2.3 ± 1.0 2.2 ± 1.1
SOFA score 2.7 ± 1.9 3.3 ± 1.8* 2.2 ± 1.8
Severe acute pancreatitis
(JPN score 3)
23 (42.6%) 15 (62.5%)* 8 (26.7%)
Pancreatic necrosis/Ischemia 33 (61.1%) 14 (58.3%) 19 (63.3%)
ANC 6 cm 20/33 (60.6%) 8/14 (57.1%) 12/19 (63.1%)
Organ failure 7 (12.9%) 5 (20.8%) 2 (6.7%)
CRP: C-reactive protein; APACHE II score: Acute Physiology and Chronic Health
Evaluation II score; SIRS score: Systemic Inﬂammatory Response Syndrome
score; SOFA score: Sequential Organ Failure Assessment score; JPN score: score
under Japanese severity scoring system; BUN: Blood Urea Nitrogen; ANC: Acute
Necrotizing Collection.
*p < 0.05, comparing rTM group to control.we found no signiﬁcant differences in outcome factors between the
rTM and control groups (length of hospital stay, need for ICU, length
of ICU stay, POF, or mortality), between the rTM and control groups
(Table 3).Differences in early treatment among enrolled patients with acute
pancreatitis
rTM administration aside, there were no signiﬁcant differences
in early treatment between patients treated by rTM and the control
group (Table 4).Changes in severity, coagulation abnormality, and inﬂammatory
response
Fig. 1 shows a summary of changes in patient severity. On day
0 (day of admission), scores for SOFA, APACHE II, and JPN scores for
patients treated by rTM were signiﬁcantly higher than for those in
the control group (p < 0.05). Such signiﬁcant differences were not
found in CRP values between the rTM and control groups on day 0.
Although all scores declined on day 3 and 7, signiﬁcant differences
on day 7 between the rTM and control groups disappeared only for
SOFA scores.
We also compared changes in activated coagulation (platelet
count, FDP, TAT, D-dimer) and inﬂammatory response (IL-6 and
HMGB-1) between the rTM and control groups on day 0, day 3, and
day 7 (Fig. 2). We found signiﬁcant differences in average platelet
count, FDP, TAT, and D-dimer between patients treated by rTM and
those in the control group on day 0 (rTM vs. control: 15.3 ± 8.6 vs.
18.8 ± 7.6  1010/L for platelet count; 40.6 ± 23.2 vs. 18.2 ± 16.7 mg/
mL for FDP; 16.8 ± 13.6 vs. 6.9 ± 3.7 mg/L for TAT; 10.8 ± 7.0 vs.
5.2 ± 5.1 mg/mL for D-dimer; p < 0.05). Levels of FDP, TAT, and D-
dimer for patients treated by rTM fell and platelet counts increased
on day 7. Thereby, the signiﬁcant differences in platelet count, FDP,
TAT, and D-dimer observed on day 0 disappeared by day 7.Table 4
Differences in treatment for enrolled patients with acute pancreatitis.
Total
n ¼ 54
rTM group
n ¼ 24
Control group
n ¼ 30
Duration of fast (days) 16.4 ± 13.4 16.4 ± 14.7 16.4 ± 12.6
Amount of ﬂuid on
the day of
admission (mL)
4432.2 ± 1155.4 4425.0 ± 1269.6 4441.3 ± 1021.5
CRAI 11 (20.4%) 4 (16.7%) 7 (23.3%)
Intravenous protease
inhibitor
54 (100%) 24 (100%) 30 (100.0%)
Duration of rTM
therapy (days)
e 9.4 ± 10.2 e
CRAI: Continuous Regional Arterial Infusion.
Fig. 1. Comparison of the mean values of the change in severity. CRP: C-reactive
protein; APACHE II score: Acute Physiology and Chronic Health Evaluation II score; SIRS
score; Systemic Inﬂammatory Response Syndrome score; SOFA score: Sequential Or-
gan Failure Assessment score; JPN score: score under Japanese severity scoring system.
*p < 0.05, comparing rTM group to control.
Table 5
Clinical outcomes patients with and without development of WON.
Development of WON
(þ)
n ¼ 24
()
n ¼ 30
Length of hospital stay (days) 46.5 ± 41.2 20.5 ± 15.3
Need for ICU care 20 (83.3%)* 16 (53.3%)
Length of ICU stay (days) 7.6 ± 4.5* 5.5 ± 6.9
Number of follow up CT/MRI
image performing within
one year from onsety
6.7 ± 3.2* 4.5 ± 2.4
Costs of follow up CT/MRI
image for one year
from onset (¥)
87,120 ± 44,470* 57,816 ± 91,156
POF 1 (4.1%) 4 (13.3%)
Mortality late 2 (8.3%) 2 (6.7%)
BUN: Blood Urea Nitrogen; ANC: Acute Necrotizing Collection; CT: Computed
Tomography; MRI: Magnetic Resonance Imaging; POF: Persistent Organ Failure.
y: CT/MRI image was performed if patients showed any new additional symptoms.
*p < 0.05, comparing WON (þ) group to WON () group.
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higher than those in the control group on day 0 (rTM vs. control:
556.8 ± 1054.2 vs. 112.9 ± 103.3 pg/mL). However, these differences
were not signiﬁcant at any time point, since SD values were very
large. Likewise, average levels of HMGB-1 among patients treated
by rTM were higher than those in the control group on day 0, but
not signiﬁcant (rTM vs. control: 24.5 ± 19.1 vs. 17.4 ± 8.5 ng/mL).Fig. 2. Comparison of the mean values of the change in coagulation abnormality, and inﬂa
bineantithrombin III complex; IL-6; Interleukin-6; HMGB-1: high morbidity group box 1. *Clinical outcomes patients with and without development of WON
Need for ICU care, length of ICU stay, number and cost of follow-
up CT/MRI within 1 year from onset were signiﬁcant worse than
those without {Need for ICU: 83.3% (20/24 patients) vs. 53.3% (16/
30 patients), length of ICU stay: 7.6 ± 4.5 vs. 5.5 ± 6.9 days, number
of follow-up CT/MRIwithin 1 year: 6.7 ± 3.2 vs. 4.5 ± 2.4, and cost of
follow-up CT/MRI within 1 year: 87,120 ± 44,470 vs. 57,816 ± 91,156
(¥); p < 0.05} (Table 5).Discussion
On the admission day, the condition of SAP patients treated by
rTM was signiﬁcantly worse than those in the control group.
Moreover, the proportion of patients who developed pancreatic
necrosis did not differ between those treated by rTM and those not
treated by rTM. However, SAP patients treated by rTM developed
WON at signiﬁcantly lower rates than those in the control group,mmatory response. FDP: ﬁbrin/ﬁbrinogen degradation products; TAT: plasma throm-
p < 0.05, comparing rTM group to control.
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two groups. This suggests that rTM may prevent the development
of WON in SAP patients.
DIC is characterized by the systemic activation of blood coagu-
lation due to endovascular damage from cytokines and/or toxic
factors (e.g., trypsin). Disturbances in microcirculation pose serious
issues for patients with DIC [17,49]. In SAP patients, DIC may affect
the progression from pancreatic ischemia to necrosis. In our study,
rTM was used to control abnormal coagulation in the early stage of
SAP; this may have prevented the development of ischemia into
necrosis, thereby reducing the rate of WON. In actual, patients
treated by rTM developed WON at a signiﬁcantly lower rate than
those not treated with rTM, in this study.
According to the revised Atlanta classiﬁcation, WON is a major
risk factor for developing SAP [37]. SAP patients with WON are
subject to high mortality ratesdroughly 30% [50e52]. Also in our
study, in patients with WON, ICU stay was more needed and its
duration was longer. Moreover, number and costs of follow-up CT/
MRI in the patients with WON was signiﬁcantly higher than those
without. Therefore, reduction of ratio of development of WON is
important to treat SAP patients. In our study, SAP patients treated
by rTM developed WON at a signiﬁcantly lower rate than those not
treated by rTM. Importantly, the severity of patients treated by rTM
was signiﬁcantly worse than non-treated, on admission day.
Thereby, their prognosis were expected to be worse. However, this
difference of prognosis failed to emerge between the two groups,
perhaps due to the lower rate at which WON developed among
those treated by rTM. To conﬁrm this hypothesis, prospective
randomized study is needed.
Initial levels of HMGB1 in our study among patients treated by
rTM was higher than those not treated with rTM. However, this
relationship was reversed on day 3: Levels of HMGB1 among pa-
tients treated by rTM appeared lower than among those not treated
with rTM. HMGB1 is released primarily by necrotic tissue. Thus,
changing levels of HMGB1 during hospital stay may support the
hypothesis that rTM helps prevent the development of necrosis.
To development of WON, two major pass ways can have
important roles; vascular damage and ﬁbrosis. Initially, vascular
damage is induced by leakage of activated protease due to
pancreatitis resulting in development of pancreatic or peripancre-
atic necrosis. Importantly, necrotic tissue can stimulate eosinophil
and mast cell which can cause ﬁbrotic responses. Thor-
ombomodulin can control abnormal coagulation, moreover, in-
hibits the activation of eosinophils and mast cells [53,54]. From
these regards, thorombomodulin might have reduced ratio of
development of WON in our study.
rTM was commonly used for patients with DIC in Japan and the
treatment of rTM was approved by Japanese health care insurance
system. In actual in this study, no serious adverse event (e.g.
bleeding) was seen in the two groups during the study period.
There are some limitations in our study. In our institution, not
few SAP patients were triaged from other hospitals. From this
reason, number of patients with development of pancreatic ne-
crosis was large. In addition, this study was carried out at a single
institution and enrolled relatively few patients. This might cause
selection bias. In addition, it was not a randomized controlled
trial; we compared two groups retrospectively. Also, in our study,
timing of CT to diagnose pancreatic necrosis/ischemia at 3 days or
later, since accuracy of conventional CT to diagnose them in the
early stage is not enough. If only patients with pancreatic
ischemia had been treated with rTM, the proportion of patients
developing WON may have been reduced still further. However,
for this study, we lacked the information to determine whether
pancreatic low density areas identiﬁed by CT represented
ischemia or necrosis.In conclusion, this study indicates that treating SAP patients
with rTM may prevent the development of WON and alter the
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